Recently, Andon Health Co.Ltd(002432) news has been frequent, and the stock price has been rising by the limit, which has aroused widespread concern in the capital market.
On January 14, Andon Health Co.Ltd(002432) announced its subsidiary ihealth labs Inc. (hereinafter referred to as “U.S. subsidiary”) issued an order of 8.1 billion yuan with the U.S. side, and immediately released the buyer’s risk of this order after hours, that is, the U.S. government has the right to terminate the contract at any time due to its own factors.
However, before the opening next Monday, Andon Health Co.Ltd(002432) released good news again. In January 16th, the company announced the rapid detection of New Coronavirus antigen by the US subsidiary, Grandpa POC (EUA), and received the authorization letter from the US Food and Drug Administration (FDA) to the US subsidiary.
Since January 10, the company has continuously released good news and walked out of a wave of continuous board market again. As of the closing on January 14, Andon Health Co.Ltd(002432) has harvested its fourth trading limit since the beginning of the year, with a share price of 75.28 yuan / share and a total market value of 36 billion yuan.
“The sharp rise of the company’s share price is caused by the resonance of its fundamentals and themes. The company’s fundamentals are expected to significantly improve its profits. The fundamentals are measurable, but the mood is not measurable. Whether the company’s market value can stand for a long time depends on the continuous development at the operational level.” Ding Kaizhong, general manager of Suzhou Zhenghe Fund Management Co., Ltd., told the Securities Daily.
On January 12 Andon Health Co.Ltd(002432) , we received another letter of concern from Shenzhen Stock Exchange, which is the fourth letter of concern received by the company since November. After the Shenzhen Stock Exchange expressed concern about whether the company selectively disclosed some information to hype the stock price and whether there were misleading statements, Andon Health Co.Ltd(002432) successively issued two large orders, which greatly boosted investor confidence and the stock price rose by the limit one after another.
On January 12, Andon Health Co.Ltd(002432) announced the current contract signing of its U.S. subsidiary in the announcement.
Among them, the US subsidiary received two orders from the Department of health of New York State on December 21, 2021 local time, with a total order amount of US $65.31 million (including freight), about RMB 416 million. Later, on January 10, 2022 local time, the US subsidiary signed a sales contract of US $120 million (including freight) with the Department of health of New York State, about 764 million yuan.
In addition, during the period from December 3, 2021 to January 5, 2022 local time, the U.S. subsidiary obtained purchase orders from the Executive Office of the Federal Department of health and human services of Massachusetts, totaling US $148 million (including freight), about RMB 944 million.
The total amount of the above orders is RMB 2.124 billion, of which the cumulative contract amount between the U.S. subsidiary and the New York State Department of health has exceeded 50% (RMB 1.004 billion) of the company’s audited main business revenue in 2020. The next day, the company’s share price continued to rise.
Then, before the opening on January 14, the company announced good news again. The U.S. subsidiary and the U.S. ACC (U.S. Army contract management headquarters) signed a procurement contract on January 13, 2022 local time to sell ihealth kit products to them. The total contract price tax is US $1.275 billion, about RMB 8.102 billion. This order is about four times the annual revenue of Andon Health Co.Ltd(002432) in 2020 (RMB 2.008 billion). Combined with the above orders, Andon Health Co.Ltd(002432) has accumulated purchase orders of more than 10 billion yuan from the U.S. government. On January 14, the company’s share price rose again.
At the beginning of the new year, we welcome the four connected boards, and the Andon Health Co.Ltd(002432) heat continues to increase. For this rising trend, Ding Kaizhong, general manager of Suzhou Zhenghe Fund Management Co., Ltd., told the Securities Daily that Andon Health Co.Ltd(002432) due to the continuous signing of huge orders by overseas subsidiaries, the fundamentals have improved significantly, superimposed the emotional impact, resulting in the accelerated inflow of funds, resulting in a sharp rise in the company’s share price. “However, the current Andon Health Co.Ltd(002432) speculation is mainly private hot money and retail investors. The emotional premium has been very obvious. At present, it has completely entered the state of chip game.” Ding Kaizhong suggested. An Guangyong, an expert member of the credit management committee of the all union M & A Association, said that the current increase of Andon Health Co.Ltd(002432) is mainly supported by external factors such as the epidemic situation, but the company itself has not found a new breakthrough in technology.
After issuing the order announcement of RMB 8.1 billion, Andon Health Co.Ltd(002432) issued a supplementary announcement on the above major contracts on January 14, in which the buyer’s risk is particularly “eye-catching”. In this risk warning, the company said that the U.S. government has the right to terminate the contract at any time due to its own factors. This risk means that the U.S. government can request to stop the execution of the contract and cancel the subsequent procurement without any reason, and the Seller shall bear the corresponding risks and possible losses.
“This message indicates the risk of Andon Health Co.Ltd(002432) . If Andon Health Co.Ltd(002432) can not obtain more market initiative in the future, it will face greater risks and uncertainties.” Jiang Han, senior researcher of Pangu think tank, told Securities Daily.
As for whether it involves the selective disclosure of some information to hype the stock price, Andon Health Co.Ltd(002432) said in its reply that the company will strengthen the integrity control of the announcement wording in the future, but it has no behavior and motivation to hype the stock price through information disclosure.
